Home > Cardiology > AHA 2020 > COVID-19 and Influenza > Meta-analyses: ACEI/ARB and COVID-19

Meta-analyses: ACEI/ARB and COVID-19

Presented By
Dr Yujiro Yokoyama, St. Luke's University Hospital
Conference
AHA 2020

Two new meta-analyses confirm that the use of angiotensin-converting-enzyme inhibitors (ACEI) and/or angiotensin-receptor blockers (ARB) is not associated with a higher susceptibility of COVID-19, nor with an increased mortality risk in COVID-19 patients [1].

COVID‐19 can infect host cells through interaction with membrane‐bound ACE2 on respiratory epithelium. Theoretically, the use of ACEI and ARB may modify susceptibility to COVID-19-infection since these drugs both increase the expression of ACE. The results of 2 new meta-analyses among ACEI and/or ARB users were presented, investigating the rate of testing positive for COVID-19 and the in-hospital mortality rate for patients with COVID-19, respectively.

The first analysis included 3 studies and demonstrated that the rates of positive testing were similar for ACEI users and non-users: OR 0.96 (95% CI 0.88–1.04; P=0.69), as well as for ARB users and non-users: OR 0.99 (95% CI 0.91–1.08; ...



Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on